Nichole Polin, MD
Cardiovascular Disease · New Orleans, LANPI 1689617805
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,650 of the $2,367 with a category attached, or 69.7%. Novartis accounts for 72.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $1,938 and has fallen 97.3% since, to $52 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in LA, where the typical reported total is $3,225.
Across 24 payments — averaging $98.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$2K
- Pfizer$333
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$92
- E.r. Squibb & Sons, L.L.C.$64
- Amgen$59
- Novo Nordisk$34
- plus $80 from 4 others
What the payments were for
- Speaking & faculty fees$1,65070%
- Food & beverage$71730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $1,704 |
| Pfizer | 7 | $333 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $92 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Amgen | 3 | $59 |
| Novo Nordisk | 1 | $34 |
| Abiomed | 1 | $26 |
| Kestra Medical Technology Services, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,367 in reported general payments places this provider in the 40th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 256 | $229,075 |
| EntrestoSacubitril/Valsartan | 191 | $193,975 |
| JardianceEmpagliflozin | 179 | $136,047 |
| Repatha SureclickEvolocumab | 146 | $105,536 |
| XareltoRivaroxaban | 36 | $29,438 |
| FarxigaDapagliflozin Propanediol | 29 | $19,362 |
| NexlizetBempedoic Acid/Ezetimibe | 28 | $16,264 |
| Praluent PenAlirocumab | 21 | $11,278 |
| VascepaIcosapent Ethyl | 16 | $8,158 |
| BrilintaTicagrelor | 11 | $6,766 |
| Atorvastatin Calcium | 463 | $4,305 |
| Metoprolol Succinate | 352 | $3,995 |
| Valsartan | 93 | $3,705 |
| Ezetimibe | 211 | $3,494 |
| Rosuvastatin Calcium | 238 | $2,494 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $333 | $229,075256 claims |
| NovartisEntresto | $1,704 | $193,975191 claims |
| Esperion Therapeutics, Inc.Nexlizet | $12 | $16,26428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Alexandra SanchezNew Orleans$69K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Yvonne GillilandNew Orleans$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.